An emerging antibacterial nanovaccine for enhanced chemotherapy by selectively eliminating tumor-colonizing bacteria
Authors:
- 14 June 2024
- journal article
- research article
- Published by Elsevier in Science Bulletin
- Vol. 69 (16) , 2565-2579
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 59 references indexed in Scilit:
- Fusobacterium nucleatum-mimicking nanovehicles to overcome chemoresistance for breast cancer treatment by eliminating tumor-colonizing bacteriaChem, 2024
- Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal CancerAdvanced Materials, 2023
- Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatmentCell, 2023
- Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancerCell, 2022
- Prebiotics‐Encapsulated Probiotic Spores Regulate Gut Microbiota and Suppress Colon CancerAdvanced Materials, 2020
- Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer OutcomesCell, 2019
- Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating AutophagyCell, 2017
- Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA AdhesinCell Host & Microbe, 2013
- Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune MicroenvironmentCell Host & Microbe, 2013
- Immunology of bacterial polysaccharide antigensCarbohydrate Research, 2003